Cargando…
1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
BACKGROUND: The indoleamine 2, 3-dioxygenase (IDO) inhibitor 1-methyl-tryptophan (1-MT) is currently being used in clinical trials in patients with relapsed or refractory solid tumors by inhibiting tumor immune escape. A greater understanding of IDO activity is required to begin to understand the mo...
Autores principales: | Ma, Huihan, Qin, Qian, Mi, Jiaqing, Feng, Qinmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488546/ https://www.ncbi.nlm.nih.gov/pubmed/32912307 http://dx.doi.org/10.1186/s40360-020-00439-w |
Ejemplares similares
-
Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022) -
Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020) -
P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer
por: Tang, Dongfang, et al.
Publicado: (2017) -
The enhanced antitumour response of pimozide combined with the IDO inhibitor L-MT in melanoma
por: Jia, Huijie, et al.
Publicado: (2018) -
IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)